DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

Launched by MCGILL UNIVERSITY · Nov 7, 2014

Keywords

ClinConnect Summary

The DOvEEgene clinical trial is focused on finding a new way to diagnose ovarian and endometrial cancers early. Researchers are developing a test that looks for specific changes in the DNA from samples collected from the cervix and uterus. By identifying these changes, the goal is to catch these cancers sooner, which can lead to better treatment outcomes and potentially save lives.

If you are a woman aged 65 to 74 and have been diagnosed with or are suspected of having cancer in the upper genital tract, you may be eligible to participate. Additionally, women who are scheduled to have surgery for non-cancerous conditions may also be included. Participants in this trial can expect to provide biofluid samples as part of their treatment plan. It’s important to know that this study is still recruiting participants, and your involvement could contribute to advancements in cancer diagnosis and treatment for many women in the future.

Gender

FEMALE

Eligibility criteria

• Case Inclusion:
• • Subjects should have suspected or confirmed cancer of the upper genital tract.
• • Participant will undergo surgery for tumour removal.
• Control inclusion:
• • • Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.